AlphAIalphai — Financial news for AI agents
GlobeNewswireNOV 134 min read$SNTI

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Senti Biosciences, Inc. ( Nasdaq: SNTI ) ( "Senti Bio" ) , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for ...

Original reporting
GlobeNewswire · Senti Biosciences, Inc.
Published Nov 13, 2025, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 14, 2025, 12:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$SNTINeutralMed
01

Why it matters

Positive clinical data could boost stock and validate platform technology, attracting investor interest.

02

Market read

The upcoming clinical data readout is a significant event for Senti Biosciences and could influence biotech sector sentiment.

03

What to watch

Broader market conditions and sector-wide trends may overshadow company-specific news; regulatory or competitive developments could also influence outcomes.

Timing: Immediate to short-term (next 1-2 weeks)

Background

Senti Biosciences is advancing gene circuit platform-based therapies, with a focus on AML. The upcoming data readout is a key milestone.

Company-level read

Ticker impact

$SNTINeutralMedium confidence
Context

Primary focus due to company's upcoming clinical data readout and financial results.

Expected impact

Potential moderate upward movement if clinical data is positive; risk of decline if results are disappointing.

Evidence & confidence

The company's upcoming data and financial results are significant catalysts, but market reaction depends on the actual data outcomes and broader biotech sector trends.

Market effects

Sector

Potential positive sentiment for biotech and healthcare sectors, especially companies involved in AML or gene therapies.

Regional

Limited regional impact; primarily affects US biotech sector.

Global

Moderate; as biotech developments can influence global healthcare innovation trends.

Counterpoint

What could challenge this read

Negative surprises in clinical data could lead to sharp declines, outweighing potential gains.

Key entities

  • Company
    Senti Biosciences, Inc.

    A biotech firm developing cell and gene therapies using proprietary gene circuit technology.

  • Organization
    American Society of Hematology (ASH)

    A professional society hosting the upcoming conference where clinical data will be presented.

Read at source← All news

Related articles

JUL 15
$SNTIMed

Senti Biosciences Holdings, Inc. (SNTI): Results of Operations and Financial Condition

Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-2.1 2 exhibit21-agreementandplan.htm EX-2.1 Document Exhibit 2.1 ______________________________________________ AGREEMENT AND PLAN OF MERGER BY AND AMONG CELADON PARTNERS SPV 35 LIMITED, SENTI MERGER SUB, INC., SENTI BIOSCIENCES HOLDING, INC., SENTI HOLDINGS, INC., AND SENTI B

SEC EDGAR 8-K6 min
SEP 2
$DEMed

Baird Upgrades Deere (DE) to Outperform on Hopes of Recovery

Baird upgraded Deere & Company (DE) to Outperform, raising its price target to $800 from $640. The firm expects DE to benefit from a recovery in North American agricultural demand, with potential earnings of $25 per share in 2027 and mid-$30s in 2028. However, DE faces challenges like declining farm income, tariffs, and cautious capital spending.

finance.yahoo.com2 min
SEP 2
$PLTRMed

Anduril Wins $65 Million Army Contract

Anduril Industries received a $65 million U.S. Army contract for mobile intelligence systems, part of a $192 million award shared with Palantir Technologies. The order includes hardware and mission shelters for eight systems, with production at Anduril’s Costa Mesa facility. Palantir USG Inc. is the program team lead. Anduril will provide four TITAN Advanced and four TITAN Basic systems, designed to process real-time data in the field.

ocbj.com2 min
SEP 2
$HSYLow

Hershey names insider Dave Hulays as CFO

Hershey named Dave Hulays as its new CFO, replacing Steve Voskuil, who will focus on strategic projects and retire in 2027. Hulays, a 12-year Hershey veteran, previously held finance roles at P&G. The company reported strong Q2 results and is expanding its snack offerings.

investing.com1 min
SEP 2
$NEEMedAI 8/10

'Trump power plant' coming to Fayette County, Pennsylvania

NextEra Energy plans to build the $13B East Riverside Energy Center in Fayette County, Pennsylvania, with a 2030-2032 completion target. The project, backed by U.S. and Japanese governments, will create 2,000 construction jobs and 100 permanent roles, adding 3,750 MW to the PJM grid. The site is a reclaimed coal mine, and NextEra was selected for its expertise in natural gas plants.

washingtonexaminer.com3 min
SEP 2
$PEPLow

Arizona Athletic Grounds scores multimillion

Arizona Athletic Grounds (AAG) announced a seven-year, multimillion-dollar partnership with PepsiCo, naming it the official soft drink partner. The deal includes PepsiCo beverages at AAG's venues and events, with signage and activation rights. AAG reported 3 million visitors in 2025 and 1.8 million in 2026, hosting major events like the 2026 FIFA World Cup Base Camp.

azbigmedia.com1 min